What's new? Log in Free sign up

Veeva Systems (VEEV)

Company Profile

Company profile

Ticker

VEEV

Exchange

Website

CEO

Mr. Peter P. Gassner

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Other Health Care

Industry (SIC)

Services - Prepackaged Software

Microsoft • Oracle • CoreWeave, Inc. Class A Common Stock • FS KKR Capital • Mobileye Global • Activision Blizzard • Gen Digital • Vmware • Adobe • Salesforce ...

Former names

VERTICALS ONDEMAND INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

VEEVA SYSTEMS INC. ...

IRS number

208235463

VEEV stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$239.40

Low target

$201.00

High target

$285.00

Truist Securities

Latest filings (excl ownership)

View all

Additional proxy soliciting materials

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

5 May 25

Registration of securities for employees

24 Mar 25

Departure of Directors or Certain Officers

Veeva Announces Fourth Quarter and Fiscal Year 2025 Results

Quarterly report

9 Dec 24

Veeva Announces Fiscal 2025 Third Quarter Results

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Jonathan Faddis

Notice of proposed sale of securities

Thomas D. Schwenger

Thomas D. Schwenger

Notice of proposed sale of securities

Eleni Nitsa Zuppas

Wagener Brian Van

Thomas D. Schwenger

Jonathan Faddis

KRISTINE DIAMOND

Financial summary

Financial statements Chart VEEV financial data

Quarter (USD)	Jan 25	Oct 24	Jul 24	Apr 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jan 25	Jan 24	Jan 23	Jan 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

VEEV institutional ownership history Ownership history

79.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	980	943	+3.9%
Opened positions	136	128	+6.3%
Closed positions	99	89	+11.2%
Increased positions	351	353	-0.6%
Reduced positions	330	324	+1.9%

13F shares	Current	Prev Q	Change
Total value	24.59 tn	23.51 tn	+4.6%
Total shares	129.42 mm	125.51 mm	+3.1%
Total puts	1.24 mm	1.13 mm	+10.5%
Total calls	1.46 mm	1.01 mm	+44.6%
Total put/call ratio	0.8	1.1	-23.5%

Largest owners	Shares	Value	Change
Vanguard	14.45 mm	$3.04 tn	+0.2%
BlackRock	10.16 mm	$2.14 tn	+5.1%
T. Rowe Price Investment Management	5.17 mm	$1.09 bn	+3.5%
Alliancebernstein	4.97 mm	$1.04 tn	-20.0%
STT State Street	3.41 mm	$717.11 bn	+3.6%
T. Rowe Price	3.30 mm	$694.39 mm	+0.1%
Massachusetts Financial Services	3.22 mm	$676.73 bn	-9.2%
FMR	3.21 mm	$675.61 bn	+7.8%
JPM JPMorgan Chase & Co.	3.01 mm	$631.93 bn	+17.5%
PFG Principal Financial	2.96 mm	$623.19 bn	+36.0%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	1.40 mm	+1.40 mm	NEW
Durable Capital Partners	0.00	-1.24 mm	EXIT
Alliancebernstein	4.97 mm	-1.24 mm	-20.0%
Artisan Partners Limited Partnership	1.42 mm	-1.20 mm	-45.9%
PFG Principal Financial	2.96 mm	+784.74 k	+36.0%
Capital International Investors	741.38 k	-692.67 k	-48.3%
Stockbridge Partners	652.84 k	+652.84 k	NEW
Marshall Wace	638.38 k	+514.00 k	+413.3%
BlackRock	10.16 mm	+494.94 k	+5.1%
RJF Raymond James Financial	455.22 k	+455.22 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VEEV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 May 25	Jonathan Faddis	Class A Common Stock	Sell	Dispose S	No	Yes	236.71	833	197.18 k	7,835
14 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	221.4006	398	88.12 k	25,889
14 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	220.7619	802	177.05 k	26,287
10 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	214.4647	870	186.58 k	27,089
10 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	212.9994	610	129.93 k	27,959
10 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	212.2346	740	157.05 k	28,569
10 Apr 25	Schwenger Thomas D.	Class A Common Stock	Sell	Dispose S	No	Yes	210.9414	380	80.16 k	29,309
4 Apr 25	Cabral Timothy S	Class A Common Stock	Sell	Dispose S	Yes	Yes	216.83	3,882	841.73 k	5,500
4 Apr 25	Diamond Kristine	RSU Class A Common Stock	Grant	Acquire A	No	No	0	872	0.00	872
4 Apr 25	Diamond Kristine	Stock Option Class A Common Stock	Grant	Acquire A	No	No	213.68	2,616	558.99 k	2,616

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

$1000 Invested In Veeva Systems 10 Years Ago Would Be Worth This Much Today

Here's How Much $100 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

Veeva Adds AI to Make Drug Development and Health Research Faster and Smarter

Veeva Systems (NYSE:VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity

Peering Into Veeva Systems's Recent Short Interest

Piper Sandler Maintains Overweight on Veeva Systems, Lowers Price Target to $255

Press releases

From Benzinga Pro

More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality

Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies PLEASANTON, Calif., May 20, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Veeva Basics is

Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit

AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and more share strategies for more connected customer experiences across sales, marketing, and medical PLEASANTON, Calif., May 6, 2025 /PRNewswire/ --

Announcing Veeva AI

Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial PLEASANTON, Calif., April 29,

Veeva Announces Research Site Clinical Trial Management System

Indero Marks 40th Study Live with Veeva RTSM

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.